Cargando…

Synchronous or Metachronous Hairy Cell Leukemia and Chronic Lymphocytic Leukemia: A Case Series and Literature Review

INTRODUCTION: Concurrent hairy cell leukemia (HCL) and chronic lymphocytic leukemia (CLL) is rare; management is inadequately described in the literature. METHODS: Retrospective chart review and clinical follow-up. RESULTS: Five patients are described. The first patient developed synchronous HCL and...

Descripción completa

Detalles Bibliográficos
Autores principales: Verma, Vivek, Giri, Smith, Bhatt, Vijaya Raj, Amador-Ortiz, Catalina, Armitage, James O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5220191/
https://www.ncbi.nlm.nih.gov/pubmed/28119853
http://dx.doi.org/10.3389/fonc.2016.00270
_version_ 1782492581923389440
author Verma, Vivek
Giri, Smith
Bhatt, Vijaya Raj
Amador-Ortiz, Catalina
Armitage, James O.
author_facet Verma, Vivek
Giri, Smith
Bhatt, Vijaya Raj
Amador-Ortiz, Catalina
Armitage, James O.
author_sort Verma, Vivek
collection PubMed
description INTRODUCTION: Concurrent hairy cell leukemia (HCL) and chronic lymphocytic leukemia (CLL) is rare; management is inadequately described in the literature. METHODS: Retrospective chart review and clinical follow-up. RESULTS: Five patients are described. The first patient developed synchronous HCL and CLL and was treated with rituximab for 13 months with HCL in remission and stable CLL. The second patient developed HCL and was treated with cladribine. His disease recurred 7 years later which was retreated with cladribine. Seven years later, he developed asymptomatic CLL. The third patient developed CLL, managed expectantly, then developed HCL 10 months later, and was treated with cladribine. Although his HCL went into remission, there was a slow redevelopment of CLL for which expectant management was done. The fourth patient developed concurrent CLL and HCL, received cladribine, with subsequent development of worsening abdominal lymphadenopathy and was lost to follow-up. The last patient developed concurrent HCL and CLL and was also diagnosed with lung adenocarcinoma; this patient was also lost to follow-up. CONCLUSION: The development of concurrent HCL and CLL may indicate a common origin. Patients with HCL may subsequently develop CLL, thus mimicking a relapse of HCL. Therapy requires individualized approach including watchful waiting in asymptomatic cases. Rituximab may be useful to treat both disorders simultaneously.
format Online
Article
Text
id pubmed-5220191
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-52201912017-01-24 Synchronous or Metachronous Hairy Cell Leukemia and Chronic Lymphocytic Leukemia: A Case Series and Literature Review Verma, Vivek Giri, Smith Bhatt, Vijaya Raj Amador-Ortiz, Catalina Armitage, James O. Front Oncol Oncology INTRODUCTION: Concurrent hairy cell leukemia (HCL) and chronic lymphocytic leukemia (CLL) is rare; management is inadequately described in the literature. METHODS: Retrospective chart review and clinical follow-up. RESULTS: Five patients are described. The first patient developed synchronous HCL and CLL and was treated with rituximab for 13 months with HCL in remission and stable CLL. The second patient developed HCL and was treated with cladribine. His disease recurred 7 years later which was retreated with cladribine. Seven years later, he developed asymptomatic CLL. The third patient developed CLL, managed expectantly, then developed HCL 10 months later, and was treated with cladribine. Although his HCL went into remission, there was a slow redevelopment of CLL for which expectant management was done. The fourth patient developed concurrent CLL and HCL, received cladribine, with subsequent development of worsening abdominal lymphadenopathy and was lost to follow-up. The last patient developed concurrent HCL and CLL and was also diagnosed with lung adenocarcinoma; this patient was also lost to follow-up. CONCLUSION: The development of concurrent HCL and CLL may indicate a common origin. Patients with HCL may subsequently develop CLL, thus mimicking a relapse of HCL. Therapy requires individualized approach including watchful waiting in asymptomatic cases. Rituximab may be useful to treat both disorders simultaneously. Frontiers Media S.A. 2017-01-09 /pmc/articles/PMC5220191/ /pubmed/28119853 http://dx.doi.org/10.3389/fonc.2016.00270 Text en Copyright © 2017 Verma, Giri, Bhatt, Amador-Ortiz and Armitage. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Verma, Vivek
Giri, Smith
Bhatt, Vijaya Raj
Amador-Ortiz, Catalina
Armitage, James O.
Synchronous or Metachronous Hairy Cell Leukemia and Chronic Lymphocytic Leukemia: A Case Series and Literature Review
title Synchronous or Metachronous Hairy Cell Leukemia and Chronic Lymphocytic Leukemia: A Case Series and Literature Review
title_full Synchronous or Metachronous Hairy Cell Leukemia and Chronic Lymphocytic Leukemia: A Case Series and Literature Review
title_fullStr Synchronous or Metachronous Hairy Cell Leukemia and Chronic Lymphocytic Leukemia: A Case Series and Literature Review
title_full_unstemmed Synchronous or Metachronous Hairy Cell Leukemia and Chronic Lymphocytic Leukemia: A Case Series and Literature Review
title_short Synchronous or Metachronous Hairy Cell Leukemia and Chronic Lymphocytic Leukemia: A Case Series and Literature Review
title_sort synchronous or metachronous hairy cell leukemia and chronic lymphocytic leukemia: a case series and literature review
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5220191/
https://www.ncbi.nlm.nih.gov/pubmed/28119853
http://dx.doi.org/10.3389/fonc.2016.00270
work_keys_str_mv AT vermavivek synchronousormetachronoushairycellleukemiaandchroniclymphocyticleukemiaacaseseriesandliteraturereview
AT girismith synchronousormetachronoushairycellleukemiaandchroniclymphocyticleukemiaacaseseriesandliteraturereview
AT bhattvijayaraj synchronousormetachronoushairycellleukemiaandchroniclymphocyticleukemiaacaseseriesandliteraturereview
AT amadorortizcatalina synchronousormetachronoushairycellleukemiaandchroniclymphocyticleukemiaacaseseriesandliteraturereview
AT armitagejameso synchronousormetachronoushairycellleukemiaandchroniclymphocyticleukemiaacaseseriesandliteraturereview